 This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH12 mutation. And, this trial is approved by medical ethics committee of hebei yanda hospital. Also, the trial has got a registry code ChiCTR-OOC-15005759 in China clinical trial registry. Researchers will conduct thsi trial from 201502 to 201712, and 100 recurrent high-grade glioma with IDH12 mutation patients will be recruited. Patients who are recruited will get PCV chemotherapy in ether Hebei Yanda Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians. 